Drug-induced liver injury secondary to tirzepatide.
Tirzepatide Research: New Case Report Flags Possible Liver Injury, Recovery After Discontinuation
BMJ Case Rep
by Cao CY, Subhaharan D, Mikhail-Gouda P et al.
“Drug-induced liver injury secondary to tirzepatide. Cao CY(1)(2), Subhaharan D(3)(4), Mikhail-Gouda P(3)(4), Haig A(3)(2). Author information: (1)Department of Digestive Health, Gold Coast University Hospital, Southport, Queensland, Australia chester.cao@health.qld.gov.au. (2)Griffith University, Gold Coast, Queensland, Australia. (3)Department of Digestive Health, Gold Coast University Hospital, Southport, Queensland, Australia. (4)Bond University, City of Gold Coast, Queensland, Australia. Tirzepatide is a dual gastric inhibitory polypeptide and glucagon-like peptide-1 receptor agonist, used for the treatment of type 2 diabetes mellitus and obesity. While gastrointestinal side effects are well described in the literature, hepatotoxicity is not a recognised complication. Recent case reports have emerged describing drug-induced liver injury associated with tirzepatide. We present a case of a woman aged in her 20s who developed acute hepatocellular injury within four weeks of commencing tirzepatide. Extensive investigations did not reveal an alternative cause of liver injury. Following the cessation of tirzepatide, the patient demonstrated clinical and biochemical recovery over the following four weeks. © BMJ Publishing Group Limited 2026. No commercial re-use. See rights and permissions. Published by BMJ Group. Conflict of interest statement: Competing interests: None declared.”
Tirzepatide just landed in the research spotlight again. A new BMJ Case Report describes a rare but notable event: acute liver injury in a young woman within four weeks of starting tirzepatide. Researchers found no other likely cause, and her liver function bounced back after stopping the compound.
Tirzepatide is already a favorite in metabolic research circles for its dual action as a GIP and GLP-1 receptor agonist. It’s best known for its impact on glucose control and obesity models. GI side effects? Well-documented. But liver-related findings like this are a curveball—hepatotoxicity isn’t typically on the radar for this peptide.
Here’s what happened:
A woman in her 20s began tirzepatide for research purposes.
Within four weeks, she showed clear signs of acute hepatocellular injury.
Extensive workup ruled out other causes.
After stopping tirzepatide, her symptoms and labs returned to normal over the next month.
Key takeaway: It’s a single case, not a trend. But it’s a flag for researchers to keep an eye on liver markers when exploring tirzepatide in new models, especially in early-phase work or unique populations.
Tirzepatide remains an exciting research compound with a lot to offer. The community is quick to adapt, and new data like this only sharpens future protocols. For more on this peptide’s mechanism and sourcing options, check out the tirzepatide page or compare suppliers in our vendor directory.
Research is about learning, adapting, and moving forward. This case is a reminder to stay curious and keep asking questions.
Related Reading
Reply: Semaglutide in Frail HFpEF: Need for Objective Functional Measures and Body Composition Assessment.
News · JACC Heart FailSemaglutide in Frail HFpEF: Need for Objective Functional Measures and Body Composition Assessment.
News · NeuropsychopharmacologyIdentification of an intrusive-hypervigilant phenotype of posttraumatic stress symptoms with unique stress peptide and amygdala functional connectivity profiles.
For Research Use Only
All content published on Pushing Peptides is intended for educational and informational purposes only. The information provided is not intended as medical advice, diagnosis, or treatment. Peptides discussed in this article are research compounds and are not approved for human therapeutic use by the FDA or any other regulatory agency. All studies referenced involve animal models or in vitro research unless otherwise stated. Consult a qualified healthcare professional before making any decisions related to your health. Pushing Peptides does not sell peptides — we are a vendor directory and educational resource.